51:(Karnofsky status <70 or Night sweats) and 'intermediate' (All Remaining) prognosis patterns identified, a significant difference was found between the survival of patients with and those without a complete response to therapy. The authors concluded that trials using a patient mix weighted toward good prognosis will not find such a difference.
291:
Patterns of survival in advanced non-Hodgkin's lymphoma. International
Conference on Malignant Lymphoma; June 13–16, 1984; Lugano, Switzerland; Proceedings: "Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances:: F. Cavalli, G. Bonadonna, M. Rozencweig, Martinus Nijhoff
50:
was employed to discover the largest sub-groupings for which survival is as extreme as possible In the clinical trials analyzed retrospectively and containing a large fraction of patients not matching the 'good' - of 'good' (Karnofsky status >80 and 'A" Symptoms and SGOT <36 U/L), 'poor'
226:
An effort was more recently undertaken to identify a similar prognostic index predictive of outcome in advanced mantle cell lymphoma. There were four factors found to have independent prognostic relevance: age, performance status, LDH, and white blood cell count (WBC).
167:
lymphomas (the majority of non-Hodgkin's lymphomas). Rituximab has significantly improved the outcomes of lymphoma patients; and its effect on the prognostic value of the IPI is uncertain. Future development of a more rigorous prognostic index may thus be useful.
62:
between 1982 and 1987. Several patient characteristics were analyzed to determine whether they were associated with differences in survival, and the factors that emerged as significant were, in addition to the Ann Arbor stage: age, elevated serum
158:
Although the IPI has shown itself to be a useful clinical tool, widely used by oncologists and a mainstay of risk stratification in clinical trials for lymphoma, it should be kept in mind that it was developed prior to the use of
176:
Given the success of the IPI for intermediate grade lymphomas, an effort was undertaken to develop a similar prognostic index for the most common low-grade lymphoma,
46:
In 1984, the first prognostic indicator for advanced non-Hodkin's lymphoma was developed. An information theory guided, computer search and evaluation procedure
301:
A predictive model for aggressive non-Hodgkin's lymphoma. The
International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987-94
234:
0 points: Age less than 50 years, ECOG performance status of 0–1, LDH less than 0.67 of the upper limit of normal, or WBC of less than 6,700 cells/mcl
127:
A simplified index can be used when comparing patients within an age group (i.e. 60 or younger, or over 60) and includes only 3 of the above factors:
272:
54:
In 1993, a retrospective analysis was performed on 2031 patients with aggressive non-Hodgkin's lymphoma, of all ages, treated with a
43:
alone, but this was increasingly found to be an inadequate means of predicting survival outcomes, and so other factors were studied.
240:
2 points: Age 60–69, ECOG performance status of 2–4, LDH 1-1.49 times the upper limit of normal, or WBC 10,000-14,000 cells/mcl
319:
Hoster et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111(2):558-565.
243:
3 points: Age 70 or greater, LDH 1.5 times the upper limit of normal or greater, and WBC of 15,000 cells/mcl or greater
36:
180:. The prognostic factors that emerged from this were: age, stage, number of lymph node areas involved, serum
163:, which is now included with anthracycline-based combination chemotherapy as of the standard of care in
64:
267:
310:
Solal-Céligny et al. Follicular lymphoma international prognostic index. Blood 2004;104(5):1258-1265.
47:
335:
177:
59:
95:
68:
237:
1 point: Age 50–59, LDH 0.67-0.99 of the upper limit of normal, or WBC 6,700 to 9,999 cells/mcl
340:
40:
39:. Previous to IPI's development, the primary consideration in assessing prognosis was the
86:
329:
214:
Intermediate risk (2 points) - 5 and 10-year survivals of 78% and 51%, respectively
55:
181:
28:
217:
High risk (3-5 points) - 5 and 10-year survivals of 53% and 36%, respectively
211:
Low risk (0-1 points) - 5 and 10-year survivals of 91% and 71%, respectively
187:
One point is assigned for each of the following adverse prognostic factors:
160:
32:
247:
The sum of the allotted points correlates with the following risk groups:
207:
The sum of the points allotted correlates with the following risk groups:
141:
The sum of the points allotted correlates with the following risk groups:
105:
The sum of the points allotted correlates with the following risk groups:
164:
79:
One point is assigned for each of the following risk factors:
292:
Publ.; Springer.com/book/10.1007/978-1-4613-2607-6, date=1985
254:
Intermediate risk (4-5 points) - median survival of 51 months
222:
Mantle Cell
Lymphoma International Prognostic Index (MIPI)
172:
Follicular
Lymphoma International Prognostic Index (FLIPI)
151:
High-intermediate risk (2 points) - 5-year survival of 46%
115:
High-intermediate risk (3 points) - 5-year survival of 43%
112:
Low-intermediate risk (2 points) - 5-year survival of 51%
148:
Low-intermediate risk (1 point) - 5-year survival of 69%
251:
Low risk (0-3 points) - median survival not yet reached
257:
High risk (6-11 points) - median survival of 29 months
118:High risk (4-5 points) - 5-year survival of 26%
109:Low risk (0-1 points) - 5-year survival of 73%
154:High risk (3 points) - 5-year survival of 32%
71:, and number of extranodal sites of disease.
8:
145:Low risk (0 points) - 5-year survival of 83%
16:Oncology tool to predict lymphoma prognosis
230:The point values are assigned as follows:
197:Greater than 4 lymph node groups involved
284:
7:
273:Continuous Individualized Risk Index
58:-based chemotherapy regimen such as
200:Serum hemoglobin less than 12 g/dL
27:) is a clinical tool developed by
14:
98:performance status of 2, 3, or 4
75:International Prognostic Index
21:International Prognostic Index
1:
268:Hodgkin's Lymphoma Prognosis
35:of patients with aggressive
101:More than 1 extranodal site
357:
191:Age greater than 60 years
83:Age greater than 60 years
31:to aid in predicting the
194:Stage III or IV disease
184:level, and serum LDH.
37:non-Hodgkin's lymphoma
65:lactate dehydrogenase
178:follicular lymphoma
203:Elevated serum LDH
137:Performance status
92:Elevated serum LDH
69:performance status
89:III or IV disease
348:
320:
317:
311:
308:
302:
299:
293:
289:
123:Age-Adjusted IPI
356:
355:
351:
350:
349:
347:
346:
345:
326:
325:
324:
323:
318:
314:
309:
305:
300:
296:
290:
286:
281:
264:
224:
174:
125:
77:
48:entropy minimax
41:Ann Arbor stage
17:
12:
11:
5:
354:
352:
344:
343:
338:
328:
327:
322:
321:
312:
303:
294:
283:
282:
280:
277:
276:
275:
270:
263:
260:
259:
258:
255:
252:
245:
244:
241:
238:
235:
223:
220:
219:
218:
215:
212:
205:
204:
201:
198:
195:
192:
173:
170:
156:
155:
152:
149:
146:
139:
138:
135:
132:
124:
121:
120:
119:
116:
113:
110:
103:
102:
99:
93:
90:
84:
76:
73:
15:
13:
10:
9:
6:
4:
3:
2:
353:
342:
339:
337:
334:
333:
331:
316:
313:
307:
304:
298:
295:
288:
285:
278:
274:
271:
269:
266:
265:
261:
256:
253:
250:
249:
248:
242:
239:
236:
233:
232:
231:
228:
221:
216:
213:
210:
209:
208:
202:
199:
196:
193:
190:
189:
188:
185:
183:
179:
171:
169:
166:
162:
153:
150:
147:
144:
143:
142:
136:
133:
130:
129:
128:
122:
117:
114:
111:
108:
107:
106:
100:
97:
94:
91:
88:
85:
82:
81:
80:
74:
72:
70:
66:
61:
57:
52:
49:
44:
42:
38:
34:
30:
26:
22:
315:
306:
297:
287:
246:
229:
225:
206:
186:
175:
157:
140:
126:
104:
78:
53:
45:
24:
20:
18:
96:ECOG/Zubrod
56:doxorubicin
29:oncologists
336:Hematology
330:Categories
279:References
182:hemoglobin
161:rituximab
33:prognosis
341:Oncology
262:See also
67:(LDH),
165:B-cell
131:Stage
87:Stage
60:CHOP
19:The
134:LDH
25:IPI
332::
23:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.